Myeloproliferative Neoplasms - MPN

Key Points

Molecular Genetics of BCR-ABL1 Negative Myeloproliferative Neoplasms

Myeloproliferative neoplasms (MPNs) are associated with dysregulation of tyrosine kinases which leads to abnormal downstream signaling of pathways and increased cellular proliferation. The presence of the BCR-ABL1 mutation characterizes chronic myelogenous leukemia. For BCR-ABL1-negative MPNs, new molecular markers have implications for further classification and diagnosis. 

Content in tables below based on Chaligné R et al, 2007; Guglielmelli P et al, 2009;  Pardanani AD et al, 2006; Schmidt AE et al, 2012; Vainchenker W et al, 2011; Vakil E et al, 2011.

JAK2
JAK2 (janus kinase 2)
Mutations
  • Chromosome location – 9p24
  • JAK2 V617F mutation
    • Prototypic tyrosine kinase mutation  
    • Gain-of-function in exon 14
  • JAK2 exon 12 mutation
    • Next most common mutation site
    • Missense, insertion, or deletion mutations
    • Observed in JAK2 V617F negative clones
  • Occurs less frequently in essential thrombocythemia (ET) or primary myelofibrosis (PMF)
Mutation Prevalence
  • JAK2 V617F mutation
  • JAK2 exon 12 mutation
    • Present in the majority of patients with PV who are JAK2 V617F-negative, but rarely occurs in PMF, ET
Biology
  • Cytoplasmic tyrosine kinase activates JAK-STAT pathway, leading to cytokine-independent growth
Disease Association
  • PV
  • ET
  • PMF
Indications
  • JAK2 V617F mutation
    • Laboratory tests suggestive of MPN
    • Unexplained erythrocytosis or thrombocytosis; bone marrow fibrosis; BCR-ABL1-negative granulocytosis; unexplained monocytosis or splenomegaly; aquagenic pruritus
    • Symptoms characteristic for MPN
      • Aquagenic pruritus
      • Unusual thrombotic events (eg, splanchinc vein thrombosis, Budd-Chiari)
      • Unexplained splenomegaly
    • Blood and bone marrow testing are equivalent – performing both is unnecessary
  • JAK2 exon 12 mutation
    • Subnormal erythropoietin and negative JAK2 V617F testing with symptoms and laboratory test results suggestive of MPN
  • Quantitative testing
    • May be useful in assessment of residual disease after stem cell transplant
    • Enhances diagnostic certainty in cases with low mutant allelic burden       
Clinical Implications
  • JAK2 inhibitors are in development
    • Decrease in mutant JAK2 V617F allelic burden may not be correlated with clinical response  
    • Utility of monitoring mutant allelic burden is under investigation
  • JAK2 V617F mutation
    • Useful in classifying the process as MPN
    • Not useful in classifying specific MPN subtypes
      • High mutant allelic burden more likely PV
      • Diagnosis based on clinical factors
    • Lower JAK2 V617F allele burden in PMF is associated with poor outcome (Guglielmelli, 2009)
ARUP Available Tests
  • JAK2 Gene, V617F Mutation, Qualitative  0051245
  • JAK2 Gene, V617F Mutation, Quantitative  0040168
  • JAK2 Exon 12 Mutation Analysis by PCR  2002357
  • Myeloproliferative Neoplasms Reflex Panel 2007418 (if V617F not detected, test reflexes to JAK2 exon 12; if JAK2 exon 12 not detected, test reflexes to MPL codon 515)
MPL

 MPL (myeloproliferative leukemia virus oncogene)

Mutations
  • Chromosome location – 1p34
  • MPL W515L or MPL W515K (rarely W515A, W515R) 
    • Resides on exon 10
    • Most common mutations
    • Activates JAK-STAT signaling
  • Observed in JAK2 V617F-negative clones
Mutation Prevalence
  • Essential thrombocythemia (ET) – 3-4%
  • Primary myelofibrosis (PMF) – 8-10%
  • Polycythemia vera (PV) – rare
Biology
  • Activating mutation of the thrombopoietin receptor causes activation of downstream signaling
  • Contributes to megakaryocytic myeloproliferation
Disease Association
  • ET
  • PMF
Indications
  • JAK2 V617F-negative individuals when suspicion for an MPN is high
  • Examples
    • Thrombocytosis and morphologically equivocal for ET
    • Marrow fibrosis and morphologically equivocal for PMF
Clinical Implications
  • Diagnostic for JAK2-negative MPN
ARUP Available Tests
  • MPL codon 515 Mutation Detection by Pyrosequencing, Quantitative  2005545
  • Myeloproliferative Neoplasms Reflex Panel 2007418 (if V617F not detected, test reflexes to JAK2 exon 12; if JAK2 exon 12 not detected, test reflexes to MPL codon 515)
PDGFRA, PDGFRB, and FGFR1

PDGFRA (platelet derived growth factor receptor, alpha-polypeptide)

PDGFRB (platelet derived growth factor receptor, beta-polypeptide)

FGFR1 (fibroblast growth receptor 1)

Mutations
  • Chromosome location
    • 4q12 (PDGFRA)
    • 5q31-33 (PDGFRB
    • 8p11 (FGFR1
  • Translocations cause fusion genes
Mutation Prevalence
  • FIP1L1-PDGFRA fusion, PDGFRB translocations, or FGFR1 translocations are most common in MPNs associated with eosinophilia
  • FGFR1 also associated with both myeloid and lymphoid neoplasms  
  • PDGFR mutations also found in chronic myelomonocytic leukemia, atypical chronic myelogenous leukemia, and rarely, chronic eosinophilic leukemia
Biology
  • PDGFRA and PDGFRB are receptor kinases that regulate cell growth and proliferation
  • FGFR1 promotes proliferation and survival of eosinophils
Disease Association
  • Eosinophilic disease
Indications
  • Unexplained persistent eosinophilia
  • Presence of any of these mutations precludes the diagnosis of eosinophilic leukemia or hypereosinophilic syndrome, and cases should be assigned to the corresponding molecular-defined categories
  • Cytogenetics may be negative for FIP1L1-PDGFRA
    • Use fluorescence in situ hybridization (FISH) analysis for detection of mutations if high suspicion
  • FGFR1 usually identified by conventional cytogenetics or FISH
Clinical Implications
  • Tyrosine kinase inhibitors (TKI) sensitivity (Imatinib)
    • FIP1L1-PDGFRA fusion – sensitive
    • PDGFRB translocation –  sensitive
    • FGFR1 mutation – not enough data to determine
  • Acquired resistance is common; however, Sorafenib may be alternative inhibitor to use  
ARUP Available Tests
  • Myeloproliferative Disorders Panel by FISH 2002360
  • Eosinophilia Panel by FISH 2002378
  • Chromosome Analysis, Bone Marrow 2002292
KIT

KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog or mast/stem cell growth factor receptor)

Mutations
  • Chromosome location – 4q12
  • D816V mutation of the tyrosine kinase domain of the KIT gene
  • Rare (<5%) juxtamembrane KIT mutations
Mutation Prevalence
  • 80% of patients with systemic mastocytosis (KIT D816V mutation)
Biology
  • KIT (CD117) is a type III tyrosine kinase
  • KIT expression is down-regulated upon differentiation of hematopoietic cells except for mast cells
  • KIT binding to its ligand (stem cell factor) regulates proliferation and maturation
Disease Association
  • Systemic mastocytosis
Indications
  • Clinical suspicion for systemic mastocytosis
  • Bone marrow with IHC positive for CD117 and flow cytometry positive for CD117, CD25, and CD2 confirm diagnosis
Clinical Implications
  • Tyrosine kinase inhibitors (TKI) sensitivity (Imatinib)
    • Sensitive
      • KIT D816V-negative
      • Rare KIT juxtamembrane domain mutations
    • Resistant
      • KIT D816V-positive
ARUP Available Tests
  • Myeloproliferative Disorders Panel by FISH 2002360
  • Eosinophilia Panel by FISH 2002378
  • Chromosome Analysis, Bone Marrow 2002292
  • CD117 (c-Kit) by Immunohistochemistry 2003806
  • Leukemia/Lymphoma Phenotyping by Flow Cytometry 2008003

Diagnosis

Indications for Testing

  • Refer to Key Points section

Criteria for Diagnosis

  • Polycythemia vera (PV)
    • Must exclude secondary causes of erythrocytosis
    • 2008 WHO diagnostic criteria – must meet both major and 1 minor criteria or the first major and 2 minor criteria
      • Major criteria
        • Evidence of increased RBC volume, including ≥1 of the following
          • Hgb >18.5 g/dL (men), >16.5 g/dL (women)
          • Hgb or Hct >99th percentile of reference
          • Elevated red cell mass >25% above mean predicted
          • Hgb >17 g/dL (men) or >15 g/dL (women) if associated with sustained increase ≥2 g/dL not attributed to correction of iron deficiency anemia
        • Presence of JAK2 V617 (90-95%) or JAK2 exon 12 mutations (5-10%)
      • Minor criteria
        • Bone marrow trilineage proliferation
        • Subnormal serum erythropoietin level
        • Endogenous erythroid colony growth in vitro
    Essential thrombocythemia (ET)
    • Must exclude other causes of thrombocytosis
      • Reactive
        • Anemias
          • Iron deficiency
          • Hemolytic
          • Acute blood loss
      • Post splenectomy
      • Inflammatory disorders
    • WHO criteria 2008 – must meet all 4 criteria
      • Sustained elevation of platelets ≥450x109/L 
        • Defined as at least 2 measurements 2 months apart
      • Bone marrow – megakaryocyte proliferation with little or no granulocyte/erythrocyte proliferation
      • Does not meet WHO criteria for BCR-ABL1-positive chronic myelogenous leukemia, polycythemia vera, primary myelofibrosis, myelodysplastic syndromes, or other myeloid neoplasm
      • Demonstration of JAK2 V617F (50%), MPL gene mutations (eg, W515L and W515K), or no evidence of reactive thrombocytosis
    • Other criteria
      • Bone marrow biopsy
        • Normal to hypercellular with increased megakaryocytes
        • Stainable iron
        • Normal red cell blood mass
        • No significant collagen or reticulin fibrosis
    Primary myelofibrosis (PMF)
    • WHO 2008 criteria – must meet all 3 major and 2 minor criteria
      • Major criteria
        • Megakaryocyte proliferation and atypia accompanied by reticulin or collagen fibrosis, or, in the absence of reticulin fibrosis, megakaryocyte changes must be accompanied by increased marrow cellularity
        • Does not meet WHO criteria for BCR-ABL1-positive chronic myelogenous leukemia, polycythemia vera, myelodysplastic syndromes, or other myeloid neoplasm
        • JAK2 V617F or other clonal markers (eg, MPL W515K/L) or no evidence of reactive fibrosis
      • Minor criteria
        • Leukoerythroblastosis
        • Increased serum lactate dehydrogenase
        • Anemia
        • Splenomegaly

Laboratory Testing

  • Initial testing – CBC with differential, erythropoietin level, uric acid, lactate dehydrogenase
  • Rule out most common causes of anemia
  • Refer to Key Points section

Histology

  • Noneosinophilic MPN (so-called "Classic MPNs")
    • Bone marrow examination is generally performed after JAK testing
      • Cytogenetic analysis
  • Eosinophilic MPN
    • Molecular testing
      • Myeloid neoplasms associated with eosinophilia and abnormalities in PDGFRA, PDGFRB, or FGFR1
      • Cytogenetic and fluorescence in situ hybridization analysis for detection of FIP1L1-PDGFFA fusion, PDGFRB (5q33) translocations, or FGFR1 (8p11) translocations
      • MPN Subtypes, Features, and Diagnostic Criteria

        MPN Subtypes, Features, and Diagnostic Criteria

        WHO Classification

        Features

        Laboratory

        AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11

        • Presents as AML
        • Myeloid sarcomas may be present at initial diagnosis or relapse
        • Morphology – acute myelomonocytic leukemia with increased eosinophils containing immature eosinophilic granules in the bone marrow
          • Peripheral eosinophilia is unusual
          • Diagnosis of AML even if blasts <20%
        • Genetics
          • inv(16)(p13.1q22) or t(16;16)(p13.1;q22) found in most cases
            • inv(16)(p13.1q22) is found in vast majority
            • FISH or PCR may be necessary to document this genetic alteration
          • Secondary cytogenetic abnormalities – +22, +8, del(7q)
          • KIT mutations may be present

        Myeloid and lymphoid neoplasms with PDGFRA rearrangement

        • Most frequently presents as CEL, but may present as AML, T-LBL, or both
          • Acute transformation can follow CEL presentation
        • Organ infiltration by eosinophils
          • Heart
          • Lungs
          • CNS
          • GI tract
        • Splenomegaly in majority of patients
        • Pronounced male predominance
        • Morphology
          • Peripheral blood and bone marrow eosinophilia (markedly elevated)
          • Typically <20% blasts in peripheral blood and bone marrow
          • Increased bone marrow mast cells common
        • Genetics
          • Absence of BCR-ABL1 fusion gene
          • Most commonly associated with FIP1L1-PDGFRA fusion
            • FISH or PCR is usually necessary to document this genetic alteration; cytogenetic studies are normal
          • Other fusion genes have rarely been identified

        Myeloid and lymphoid neoplasms with PDGFRB rearrangement

        • Presents with features of chronic myelomonocytic leukemia (usually with eosinophilia)
        • Splenomegaly in majority of patients
        • Male predominance, but much less marked than PDGFRA-associated neoplasms
        • Morphology
          • Peripheral leukocytosis
          • Hypercellular BM with typically <20% blasts
          • Increased bone marrow mast cells common
        • Genetics
          • Most common translocation-t(5;12)(q31-33;p13) resulting in formation of ETV6-PDGFRB

        Myeloid and lymphoid neoplasms with FGFR1 abnormalities

        • Often presents with peripheral eosinophilia in the context of lymphadenopathy and lymphoblastic leukemia/lymphoma
        • Slight male predominance
        • Morphology
          • AML, ALL, CEL (usually associated with peripheral blood or bone marrow eosinophilia)
        • Genetics
          • Presence of t(8;13)(p11;q12) or a variant translocation at the 8p11 breakpoint leading to FGFR1 rearrangement
          • Secondary cytogenetic abnormalities – trisomy 21 most often observed
      • In the absence of these molecular markers, chronic eosinophilic leukemia (CEL), not otherwise specified (NOS) (CEL-NOS), or hypereosinophilic syndrome (HES) should be considered
        • Diagnosis in both CEL-NOS and HES requires the following
          • Presence of ≥1.5x109/L eosinophil count – peripheral blood
          • Exclusion of secondary eosinophilia
          • Exclusion of other acute or chronic myeloid neoplasm
          • No evidence for phenotypically abnormal or clonal T lymphocytes
        • Diagnosis of HES requires the absence of both cytogenetic abnormality and ≥2% peripheral blasts or ≥5% bone marrow blasts
  • Mast cell MPNs – CD117 (c-Kit), CD25 testing

Prognosis

  • Classic MPN
    • JAK2 V617F – quantitative testing may predict degree of fibrosis, thrombotic tendencies, or survival
    • Karyotyping in PMF
      • Unfavorable – complex karyotype or ≥1 abnormality, including +8, -7/7q-, i(17q), -5/5q-, 12p-, inv(3), or 11q23
  • Eosinophilic MPN
    • inv(1) - favorable prognosis unless associated with KIT mutation
    • PDGFRA and PDGFRB - good prognosis with favorable response to tyrosine kinase inhibitors (TKIs)
    • FGFR1 - poor prognosis with unclear response to TKIs

Differential Diagnosis

Clinical Background

Myeloproliferative neoplasms (MPN) are a group of slow-growing blood cancers, including chronic myelogenous leukemia (CML). MPNs present with clonal proliferation of abnormal hematopoietic cells that involve bone marrow and peripheral blood.

Classification

2008 WHO Classification of Myeloid Neoplasms and Acute Leukemia

Myeloproliferative neoplasms (MPN)

  • CML, BCR-ABL1 positive1
  • Chronic neutrophilic leukemia
  • Polycythemia vera1
  • Primary myelofibrosis1
  • Essential thrombocythemia1
  • Chronic eosinophilic leukemia (CEL), not otherwise specified (NOS)
  • Mastocytosis
    • Cutaneous mastocytosis
    • Systemic mastocytosis
    • Mast cell leukemia
    • Mast cell sarcoma
    • Extracutaneous mastocytoma
  • MPN, unclassifiable
Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1

Myelodysplastic/myeloproliferative neoplasms

  • Chronic myelomonocytic leukemia
  • Atypical CML, BCR-ABL1 negative
  • Juvenile myelomonocytic leukemia
  • Myelodysplastic/myeloproliferative neoplasm, unclassifiable
  • Refractory anemia with ring sideroblasts associated with marked thrombocytosis2
Myelodysplastic syndromes
Acute myeloid leukemia (AML) and related precursor neoplasms
Acute leukemias of ambiguous lineage
1Considered classic MPN
2Provisional listing; subject to change

Selected MPNs

  • Polycythemia vera (PV)

    Epidemiology

    • Erythroid dominant trilineage proliferation of hematopoietic precursor cells
    • Incidence – 2.8/100,000
    • Age – peaks in 50s-60s
    • Sex – M>F (minimal)

    Clinical Presentation

    • Insidious onset
    • Thrombotic complications
    • Bleeding complications – often associated with acquired von Willebrand disease
      • Epistaxis
      • Oral mucosal hemorrhage
      • Gastrointestinal hemorrhage
      • Ecchymoses
    • Hyperviscosity syndrome – less common
      • Hypertension
      • Headache
      • Dizziness
      • Visual disturbances
      • Claudication
    • Erythromelalgia
      • Redness and burning of palms and plantar areas of feet – sometimes progressing to necrosis of digits
    • Gouty arthritis
    • Pruritus
    • Hepatosplenomegaly
    • Transformation to myelofibrosis (or spent phase) – short survival
    • Transformation to acute leukemia – always fatal without allogeneic bone marrow transplant
    Essential thrombocythemia (ET)

    Epidemiology

    • Thrombocytosis and abnormal megakaryocyte proliferation with clonal proliferation of pluripotent stem cells
    • Incidence – 1.5/100,000
    • Age – peaks in 50s 
      • Secondary peak in 20s – mainly females; M<F, 1:2
    • Sex – M:F, equal 

    Clinical Presentation

    • Arterial thrombosis
      • Brain
      • Cardiac
      • Extremities
    • Venous thrombosis
    • Bleeding complications
    • Many patients are asymptomatic and do not require therapy
    • Transformation to myelofibrosis (or spent phase) in <10% of cases – short survival
    • Transformation to acute leukemia in <5% of cases – always fatal without allogeneic bone marrow transplantation
    Primary myelofibrosis (PMF)

    Epidemiology

    • Clonal stem cell deficit characterized by panmyelosis with intact maturation, progressive bone marrow fibrosis, splenomegaly, multiorgan extramedullary hematopoiesis
    • Incidence – 0.3-1.5/100,000 per year
    • Age – mean is 67 years
    • Sex – M:F, equal

    Clinical Presentation

    • May be a secondary process in polycythemia vera and essential thrombocythemia
    • Shortest survival of all MPNs
    • Some with insidious onset and stable; others rapidly progressing
    • Acute leukemic transformation common
    • Symptoms, physical and laboratory findings
      • Hypercatabolic state – fever, weight loss, night sweats
      • High output cardiac failure from increased plasma volume
      • Blood abnormality – dacryocytes (tear drops), leukoerythroblastic morphology
      • Other blood abnormalities – anemia, leukocytosis, leukopenia, thrombocytosis, thrombocytopenia, increased circulating blasts
      • Fatigue unrelated to anemia
      • Dyspnea secondary to anemia
      • Petechia secondary to thrombocytopenia
      • Gout
      • Splenomegaly – 100% of patients
      • Hepatomegaly – 50% of patients

Pediatrics

Myeloproliferative neoplasms are extremely rare in children.

Polycythemia vera (PV)

Epidemiology

  • Incidence – rare
  • Age
    • <0.1% with PV are <20 years
    • Two peaks – 5-6 years, 10-14 years

Clinical Presentation

  • Thromboses
    • Arterial – stroke
    • Venous – Budd-Chiari syndrome
  • Bleeding disorders
  • Splenomegaly common
  • Rubor
  • Pruritus – especially after hot bath
  • Erythromelalgia

Diagnosis

Indications for Testing

  • Refer to Key Points section

Criteria for Diagnosis

  • See Diagnosis tab for PV criteria

Laboratory Testing

  • Initial diagnosis – CBC with differential, uric acid, lactate dehydrogenase
  • Refer to Key Points section

Indications for Laboratory Testing

  • Tests generally appear in the order most useful for common clinical situations
  • Click on number for test-specific information in the ARUP Laboratory Test Directory
Test Name and Number Recommended Use Limitations Follow Up
Erythropoietin 0050227
Method: Quantitative Chemiluminescent Immunoassay

Initial test for MPN

Use to identify or exclude polycythemia vera (PV) – minor criteria

   
JAK2 Gene, V617F Mutation, Qualitative 0051245
Method: Polymerase Chain Reaction

First-line test in the workup of unexplained erythrocytosis or thrombocytosis after exclusion of secondary causes

Aids in the workup of classic BCR-ABL1-negative myeloproliferative neoplasms (PV, essential thrombocythemia [ET], primary myelofibrosis [PMF])

Clinical sensitivity – 90-95% in PV, ~50% in ET and PMF

JAK2 exon 12 mutations not detected

Limit of detection is 0.5% mutant alleles

Results are not diagnostic of any single MPN

Negative JAK2 V617F result does not rule out the presence of a JAK2 c.1849G>T (V617F) mutation or the possible diagnosis of PV, ET, or PMF

Mutation must exist within the granulocyte population to be detected

Bone marrow biopsy

Can confirm result with JAK2 V617F mutation, quantitation testing

JAK2 Gene, V617F Mutation, Quantitative 0040168
Method: Polymerase Chain Reaction

Enhanced diagnostic certainty in suspected cases with low mutant allele burden

Aids in MRD monitoring post stem cell transplant

Clinical sensitivity – 90-95% in PV, ~50% in ET and PMF

JAK2 exon 12 mutations are not detected

Limit of detection is 0.2%

Bone marrow biopsy
JAK2 Exon 12 Mutation Analysis by PCR 2002357
Method: Polymerase Chain Reaction

Most useful in JAK V617F individuals with suspected PV, erythrocytosis, and subnormal erythropoietin (EPO)

Limit of detection – 1/10,000 cells

 
MPL codon 515 Mutation Detection by Pyrosequencing, Quantitative 2005545
Method: Polymerase Chain Reaction/Quantitative Pyrosequencing

Due to the rarity of this mutation, this test should be limited to individuals suspected of PV, negative JAK2 V617F studies (including exon 12), and a confirmed low EPO level

Limit of detection – 5% mutant alleles

 
Myeloproliferative Neoplasms Reflex Panel 2007418
Method: Polymerase Chain Reaction/Pyrosequencing

Panel for the workup of unexplained erythrocytosis or thrombocytosis after exclusion of secondary causes

If JAK2 V617F is not detected, JAK2 exon 12 mutation analysis is added

If JAK2 exon 12 mutation is not detected, MPL codon 515 mutation detection is added

Clinical sensitivity – 90-95% in PV, ~50% in ET and PMF

Results are not diagnostic of any single MPN

Negative JAK2 V617F result does not rule out the presence of a JAK2 c.1849G>T (V617F) mutation or the possible diagnosis of PV, ET, or PMF

Bone marrow biopsy

Can confirm result with JAK2 V617F mutation, quantitation testing

Myeloproliferative Disorders Panel by FISH 2002360
Method: Fluorescence in situ Hybridization

Limited role in the work-up of classical MPNs in the setting of an otherwise optimal cytogenetic study

Provides prognostic and predictive information in MPNs presenting with eosinophilia

Detects both cryptic and noncryptic BCR-ABL1 translocations in suspected CML

Probes included – BCR/ABL, PDGFRA,  PDGFRB, and FGFR1

Only detects rearrangements targeted by the probes

The translocation partners of the PDGFRB gene on 5q33 and FGFR1 gene on 8p11 have multiple translocation partners; these translocation partners are not identified by this test

 
Eosinophilia Panel by FISH 2002378
Method: Fluorescence in situ Hybridization

Diagnosis, prognosis, and monitoring for newly diagnosed acute or chronic leukemia with eosinophilia

Probes included – PDGFRA, PDGFRB, FGFR1, and CBFB

Does not detect rearrangements associated with chronic myelogenous leukemia

Translocation partners of PDGFRB on gene 5q33 and FGFR1 on gene 8p11 are not identified by this test

 
Chromosome Analysis, Bone Marrow 2002292
Method: Giemsa Band

Detect chromosome abnormalities in bone marrow for suspected acute or chronic leukemia with eosinophilia

Can also aid in distinguishing this class of hematologic disorders from CML

 

Repeat testing as clinically indicated to monitor disease progression

Chromosome FISH, Interphase 2002298
Method: Fluorescence in situ Hybridization

May aid in classification, prognostication, and therapeutic monitoring

Specific FISH probes must be requested and for this indication include PDGFRA, PDGFRB, +8, +9, 20q deletion, monosomy 7/7q deletion, 5q deletion, and 13q deletion

ARUP Oncology FISH Probes menu

Limit of detection is probe dependent and around 2-5% in interphase nuclei

Many of these abnormalities can also be detected in myelodysplastic syndromes and AML and are therefore not sufficient for diagnosis but are consistent with the suspected diagnosis (exception is PDGFRA and PDGFRB, which are specific for MPNs)

Repeat testing as clinically indicated to monitor disease progression

CD117 (c-Kit) by Immunohistochemistry 2003806
Method: Immunohistochemistry

Aid in histologic diagnosis of MPN

Stained and returned to client pathologist; consultation available if needed

   
CD25 by Immunohistochemistry 2003544
Method: Immunohistochemistry

Aid in histologic diagnosis of MPN

Stained and returned to client pathologist; consultation available if needed

   
Leukemia/Lymphoma Phenotyping by Flow Cytometry 2008003
Method: Flow Cytometry

Aid in evaluation of hematopoietic neoplasms (ie, leukemia, lymphoma)

Monitor therapy in patients with established diagnosis of hematopoietic neoplasms

Specimens include peripheral blood, bone marrow, and tissue

Markers selected based on clinical history, previous flow studies, and pathologist interpretation

Available markers

T cell: CD1, CD2, CD3, CD4, CD5, CD7, CD8, TCR alpha-beta, TCR gamma-delta, Cytoplasmic CD3

B cell: CD10, CD19, CD20, CD22, CD23, CD103, Kappa, Lambda, FMC7, Cytoplasmic Kappa, Cytoplasmic Lambda

Myelo/Mono: CD11b, CD13, CD14 (Mo2), CD14 (MY4), CD15, CD33, CD64, CD117, myeloperoxidase

Misc: CD11c, CD16, CD25, CD30, CD34, CD38, CD41, CD42b, CD45, CD56, CD57, CD61, HLA-DR, glycophorin, TdT, bcl-2, ALK-1, CD123, CD138, CD200, CD26, CD45

   
Leukemia/Lymphoma Phenotyping by Flow Cytometry 2008003
Method: Flow Cytometry

Aids in diagnosis of hematopoietic neoplasms (ie, leukemia, lymphoma)

Monitor therapy in patients with established diagnosis of hematopoietic neoplasms

Specimens include peripheral blood, bone marrow, and tissue

Markers selected based on clinical history, previous flow studies, and pathologist interpretation

Available markers

T cell: CD1, CD2, CD3, CD4, CD5, CD7, CD8, TCR alpha-beta, TCR gamma-delta, Cytoplasmic CD3

B cell: CD10, CD19, CD20, CD22, CD23, CD103, Kappa, Lambda, FMC7, Cytoplasmic Kappa, Cytoplasmic Lambda

Myelo/Mono: CD11b, CD13, CD14 (Mo2), CD14 (MY4), CD15, CD33, CD64, CD117, myeloperoxidase

Misc: CD11c, CD16, CD25, CD30, CD34, CD38, CD41, CD42b, CD45, CD56, CD57, CD61, HLA-DR, glycophorin, TdT, bcl-2, ALK-1, CD123, CD138, CD200, CD26, CD45

   
Oxygen Dissociation (P50) by Hemoximetry 2002984
Method: Spectrophotometry/Clark Electrode

Use when JAK2 testing negative and PV present

   
von Hippel-Lindau (VHL) Sequencing 2002970
Method: Polymerase Chain Reaction/Sequencing

Use when JAK2 testing negative and PV present

Large deletions and duplications, deep intronic mutations, and regulatory region mutations are not detected

Rare diagnostic errors may occur due to primer-site mutations

PV due to causes other than VHL gene mutations are not detected

 
Additional Tests Available
 
Click the plus sign to expand the table of additional tests.
Test Name and NumberComments
CBC with Platelet Count and Automated Differential 0040003
Method: Automated Cell Count/Differential

Initial screen for MPN

EPOR Mutation Detection by Sequencing 2007914
Method: Polymerase Chain Reaction/Sequencing

Confirm a diagnosis of familial or congenital polycythemia (PFPC)